West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Big Pharma spends millions of dollars on federal lobbying to protect its interests and prevent fair competition in the ...

Pharmaceutical companies are cautiously stepping ... fierce competition in the GLP-1 space, the rise of community-based trials, and a more grounded perspective on decentralised clinical trials ...

Discover key insights from West Pharmaceutical Services' Q4 2024 earnings call, highlighting growth in GLP-1 elastomers, biologics, and HVP components.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Both pharma giants have had difficulty producing enough of the drugs to meet demand. And though each saw their stocks soar due to GLP-1s, there is a better way to play the market. Over the past ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical ... a prescription medicine. GLP-1 agonist semaglutide ...

GLP-1 Receptor Agonist Market is estimated to be valued at USD 25.10 Bn in 2024 and is expected to reach USD 55.70 Bn by 2031, exhibiting a CAGR of 12.1%. BURLINGAME, CA, UNITED STATES, February 4 ...

JB Pharma share price: The market capitalisation ... JB is unlikely to target the GLP-1 drugs a it does not have an established diabetes franchisee.” GLP-1 drugs or Glucagon-like peptide-1 ...

Hims & Hers revealed that it will make its Big Game debut with a minute-long ad highlighting its compounded GLP-1 weight loss drug offerings ... with support from Little Moving Pictures. Hims & Hers’ ...